EMEA-001794-PIP02-16-M03
Key facts
| Active substance |
Vamorolone
|
| Therapeutic area |
Other
|
| Decision number |
P/0080/2021
|
| PIP number |
EMEA-001794-PIP02-16-M03
|
| Pharmaceutical form(s) |
Oral suspension
|
| Condition(s) / indication(s) |
Treatment of Duchenne muscular dystrophy
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
ReveraGen BioPharma Ltd
Tel. +1 3017627980 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|